CE-224,535

DRUG3 trials

Sponsors

Pfizer

Conditions

Arthritis, RheumatoidHealthy VolunteersRheumatoid Arthritis

Phase 1

Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis

CompletedNCT00446784

PfizerArthritis, Rheumatoid

Start: 2007-04-30End: 2007-08-31Target: 20Updated: 2011-05-23

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

CompletedNCT00838058

PfizerHealthy Volunteers, Rheumatoid Arthritis

Start: 2009-01-31End: 2009-03-31Updated: 2009-10-14

Phase 2

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

CompletedNCT00628095

PfizerArthritis, Rheumatoid

Start: 2008-04-07End: 2009-02-04Updated: 2022-04-04

Related Papers

Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.

2012-03-01199 citations